Akoya Biosciences, Inc.
AKYA
$1.16
$0.021.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -14.55% | -15.48% | -4.98% | 9.66% | 17.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.55% | -15.48% | -4.98% | 9.66% | 17.89% |
| Cost of Revenue | -25.72% | -16.20% | -7.39% | 5.09% | 21.88% |
| Gross Profit | -5.77% | -14.97% | -3.14% | 13.30% | 14.93% |
| SG&A Expenses | -20.29% | -20.66% | -16.45% | -9.79% | -0.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.45% | -19.53% | -15.79% | -8.39% | 1.35% |
| Operating Income | 33.03% | 26.50% | 31.14% | 30.54% | 17.93% |
| Income Before Tax | 30.22% | 12.74% | 18.95% | 21.05% | 6.83% |
| Income Tax Expenses | 77.03% | 265.00% | 266.67% | 145.24% | -43.08% |
| Earnings from Continuing Operations | 30.10% | 12.57% | 18.81% | 20.96% | 6.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.10% | 12.57% | 18.81% | 20.96% | 6.90% |
| EBIT | 33.03% | 26.50% | 31.14% | 30.54% | 17.93% |
| EBITDA | 36.20% | 28.87% | 34.61% | 35.55% | 22.13% |
| EPS Basic | 34.86% | 24.53% | 33.27% | 37.73% | 23.44% |
| Normalized Basic EPS | 28.27% | 28.23% | 39.28% | 42.32% | 29.95% |
| EPS Diluted | 34.86% | 24.53% | 33.27% | 37.73% | 23.44% |
| Normalized Diluted EPS | 28.27% | 28.23% | 39.28% | 42.32% | 29.95% |
| Average Basic Shares Outstanding | 5.46% | 11.66% | 18.84% | 26.99% | 23.74% |
| Average Diluted Shares Outstanding | 5.46% | 11.66% | 18.84% | 26.99% | 23.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |